NewEdge Wealth LLC Purchases 18,875 Shares of Novartis AG $NVS

NewEdge Wealth LLC lifted its position in shares of Novartis AG (NYSE:NVS) by 3.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 505,339 shares of the company’s stock after buying an additional 18,875 shares during the quarter. Novartis comprises 0.8% of NewEdge Wealth LLC’s holdings, making the stock its 24th biggest position. NewEdge Wealth LLC’s holdings in Novartis were worth $69,671,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. increased its position in Novartis by 77.7% during the third quarter. Raymond James Financial Inc. now owns 1,648,174 shares of the company’s stock worth $211,362,000 after acquiring an additional 720,860 shares during the period. CIBC Bancorp USA Inc. bought a new stake in Novartis in the 3rd quarter valued at about $64,563,000. Bank of Montreal Can boosted its holdings in Novartis by 85.0% in the 3rd quarter. Bank of Montreal Can now owns 1,045,191 shares of the company’s stock valued at $134,035,000 after purchasing an additional 480,201 shares during the period. Tidal Investments LLC grew its position in shares of Novartis by 3,309.5% during the 3rd quarter. Tidal Investments LLC now owns 301,436 shares of the company’s stock worth $38,656,000 after purchasing an additional 292,595 shares in the last quarter. Finally, Woodley Farra Manion Portfolio Management Inc. increased its holdings in shares of Novartis by 78.0% during the third quarter. Woodley Farra Manion Portfolio Management Inc. now owns 606,780 shares of the company’s stock worth $77,813,000 after purchasing an additional 265,861 shares during the period. Institutional investors own 13.12% of the company’s stock.

Key Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Zacks Research raised its earnings estimate for Q3 2026 to $2.30 from $2.28, suggesting slightly better mid-year profitability expectations.
• Positive Sentiment: Zacks Research increased its Q4 2026 EPS forecast to $2.23 from $2.08, a meaningful upward revision for late-2026 earnings.
• Positive Sentiment: Erste Group Bank also nudged up its FY2027 EPS estimate to $9.77 from $9.74, reinforcing a generally constructive longer-term view. Novartis stock page
• Neutral Sentiment: Analyst consensus still calls for FY2026 EPS of $8.86, while Zacks’ revised FY2026 estimate of $8.75 remains close to that level, indicating expectations are largely intact.
• Negative Sentiment: Zacks cut Q2 2026 EPS to $2.24 from $2.37 and trimmed FY2026 guidance, which may temper enthusiasm about near-term growth.
• Negative Sentiment: Additional reductions to Q1 2027, Q2 2027, and Q4 2027 estimates point to some caution around future earnings momentum.

Analyst Upgrades and Downgrades

NVS has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Citigroup reissued a “buy” rating on shares of Novartis in a research report on Thursday, February 5th. Sanford C. Bernstein upgraded Novartis to a “hold” rating in a research note on Thursday, March 19th. Morgan Stanley upped their target price on Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research report on Thursday, March 26th. Finally, Argus raised Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Wednesday, March 11th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $141.20.

Novartis Price Performance

Shares of NYSE:NVS opened at $145.98 on Friday. The firm has a 50 day moving average of $153.19 and a 200-day moving average of $144.31. The stock has a market capitalization of $278.56 billion, a PE ratio of 20.91, a PEG ratio of 2.56 and a beta of 0.46. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. Novartis AG has a 12 month low of $104.93 and a 12 month high of $170.46.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). The firm had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.The business’s revenue was down .9% on a year-over-year basis. During the same period last year, the company posted $2.28 EPS. On average, equities research analysts predict that Novartis AG will post 8.85 EPS for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.